Quizartinib Dihydrochloride is the dihydrochloride salt form of quizartinib, an orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. It is grouped under the following drug class(es): Tyrosine Kinase Inhibitors. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include AC-220 dihydrochloride and vanflyta. Its PubChem CID is 25184035.
Quizartinib dihydrochloride
| CAS No | 1132827-21-4 |
|---|---|
| Molecular Formula | C29H34Cl2N6O4S |
| Molecular Weight | 633.6 g/mol |
| Synonyms | 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea;dihydrochloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Quizartinib Dihydrochloride is the dihydrochloride salt form of quizartinib, an orally available small molecule with potential antineoplastic activity.
The listed CAS number is 1132827-21-4.
The listed molecular formula is C29H34Cl2N6O4S.
The listed molecular weight is 633.6 g/mol.
1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea;dihydrochloride.
The source lists AC-220 dihydrochloride and vanflyta.